The United Kingdom ceased to be a member state of the European Union on 31st January 2020, with the Brexit transition period ending on 31st December of the same year.

No matter one’s political beliefs, it is inarguable that there has been a far-reaching impact on the life sciences industry in both the UK and the EU, especially for the manufacturers, producers, importers, and exporters of pharmaceuticals, biopharmaceuticals, medical devices, food supplements and their suppliers.

This whitepaper looks to assess the impact on the industry through research carried out by survey on a cross-section of companies across a range of sectors — download this resource below.